Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;12(4):279-293.
doi: 10.1111/1753-0407.13007. Epub 2019 Dec 11.

Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials

José Silva-Cardoso  1 , Omar Sheikh  2 , Mouhamed Nashawi  2 , Son Pham  2 , Kelly M Gallegos  2 , Laith R Dinkha  2 , Robert J Chilton  2
Affiliations
Review

Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials

José Silva-Cardoso et al. J Diabetes. 2020 Apr.

Abstract
in English, Chinese

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs that were primarily developed for the treatment of type 2 diabetes mellitus. However, these agents have shown to provide additional beneficial effects. We will discuss three main topics regarding the use of SGLT2 inhibitors: noncardiovascular effects, cardiovascular benefits, and novel clinical indications. Multiple clinical trials and preliminary studies across varying disciplines have shown that these agents exhibit cardiorenal-protective benefits, retinoprotective benefits, and may aid in weight loss without causing marked hypoglycemia. Therefore, these agents represent an avenue in clinical practice to manage comorbid conditions in the hyperglycemic patient. Because of their multifaceted effects and robust action, SGLT2 inhibitors represent therapy options for providers that not only provide beneficial clinical results but also reduce total patient drug burden.

钠-葡萄糖协同转运蛋白-2(SGLT2)抑制剂是一类主要用于治疗2型糖尿病的药物。然而, 这些制剂已经显示额外的益处。我们将讨论有关SGLT2抑制剂使用的三个主要方向:非心血管效果、心血管益处和新的临床适应症。跨学科的多项临床试验和初步研究表明, 这些药物显示出保护心肾以及视网膜的好处, 并可能有助于减肥, 而且不会导致明显的低血糖。因此, 这些药物代表了临床实践中管理高血糖患者共存疾病的一条途径。由于SGLT2抑制剂的多方面效应和强大的作用, SGLT2抑制剂提供了新的治疗选项, 不仅有好的临床结果, 而且减少了患者的总药物负担。.

Keywords: SGLT2 inhibitors; SGLT2抑制剂; diabetic nephropathy; heart failure; macrovascular; microvascular; retinopathy; translational biology; 大血管; 微血管; 心衰; 糖尿病肾病; 视网膜病变; 转化生物学.

PubMed Disclaimer

References

REFERENCES

    1. Gyberg V, De Bacquer D, De Backer G, et al; EUROASPIRE Investigators. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol. 2015;14:133.
    1. Dickinson JK, Guzman SJ, Maryniuk MD, et al. The use of language in diabetes care and education. Diabetes Care. 2017;43:551-564.
    1. Zinman B, Wanner C, Lachin JM, et al; for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
    1. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101:44-51.
    1. Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:e4-e5.

MeSH terms

LinkOut - more resources